Two features set the pace observed in trials: Long half-life
doi: 10.1038/s41593-018-0100-x 5 AkiyamaH.BargerS.BarnumS.BradtB.BauerJ.ColeG
In addition, for maintained platelet function, peripherally and centrally as a particular vascular and multiorgan failure occlusion/occlusion-like syndrome, above described, was clearly responsive to the BPC 157 therapy application [40,41,42,43,47,48,49,50,51,52,53,54,55,56], given eliminated/annihilated hemorrhage (i.e., brain, lung) and thrombosis, in particular of consideration of pulmonary embolism [87] and evidently, reversed already advanced Virchow triad circumstances [40,41,42,43,47,48,49,50,51,52,53,54,55,56]
10.1111/j.1751-1097.1987.tb04855.x 96 NicolosiV.ChhowallaM.KanatzidisM